Investing in innovation – new digital approaches for a new decade
For the first time in history, we have the technologies that will allow us to develop new therapies and tools that can shift the paradigm from ‘disease care’ to true healthcare. As part of BIO-Europe Spring, Paul Tunnah sat down for a fireside chat with Johnson & Johnson Innovation’s Dr William Hait to find out how his company is hoping to accelerate this shift through the convergence of digital and traditional R&D – including strategic approaches in data science and technology, and new collaborations in genomics medicine.
About the interviewee
Dr William N Hait, is global head of Johnson & Johnson External Innovation. He joined Johnson & Johnson in 2007 and served as global therapeutic area head for Oncology from 2009 to 2011, and then as global head, Janssen Research & Development, from 2011 through 2018. Before that, he was a medical oncologist and founding director of The (Rutgers) Cancer Institute of New Jersey.
This video was produced in partnership with Johnson & Johnson and EBD Group.
About EBD Group
EBD Group helps collaborations get started across the life science value chain. The fourteenth annual BIO-Europe Spring international partnering conference was a fully digital event and welcomed over 1,700 delegates from 986 companies online for nearly 6,000 virtual partnering meetings, with 12 recorded panels featuring industry experts.